Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing s Syndrome

Go Back to All Clinical Trials

Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing s Syndrome

Brief description of study

This is a non-interventional, multinational, multi-center study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome (CS). This study is observational in nature and does not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule. Patients with Endogenous CS who are treated with osilodrostat alone or in combination with other therapies will be considered eligible for study enrollment. Each patient enrolled in the study will be followed up for 3 years from study entry. Patients who discontinue prior to the end of the 3-year period will be followed-up for 3 months after discontinuation of osilodrostat and will be included in the analysis. The maximum duration for the individual patient is 3 years.

Clinical Study Identifier: s22-01110

Principal Investigator: Nidhi Agrawal.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies